Non steroidal anti-inflammatory drugs. Minimising the harm, maximising the benefit.
Hawkey
C J
CJ
Division of Gastroenterology, University Hospital, Nottingham, United Kingdom.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D005753:Gastric Mucosa / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology; D007527:Isoenzymes / Q000187:drug effects; D008565:Membrane Proteins; D009853:Omeprazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000139:chemically induced* / Q000517:prevention & control; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D007527:Isoenzymes; D008565:Membrane Proteins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D009853:Omeprazole